2021

MaaT Pharma Presents Promising Clinical Data from 76 Patients with Acute Graft-vs-Host-Disease Treated with MaaT013 at 63rd ASH Annual Meeting…

MaaT Pharma S.A. (« MaaT Pharma » ou la « Société »), société française de biotechnologies en stade clinique avancé,…

This announcement is not being made in and copies of it shall not be distributed or sent, directly or indirectly,…

MaaT Pharma Will Host Investor Information Meeting Following Presentation at ASH Conference of Additional Results on MaaT013 Comments on results…

Not for release, publication or distribution, in whole or in part, directly or indirectly in or into the United States…

Ce communiqué ne peut être publié, distribué ou diffusé, directement ou indirectement, aux Etats-Unis d’Amérique, en Australie, au Canada ou…

Results from HERACLES trial in 24 patients with GI-predominant, steroid-resistant grade III-IV aGvHD and from EAP program in 52 patients…

[image_with_animation image_url=”5200″ animation=”None” hover_animation=”none” alignment=”” border_radius=”none” box_shadow=”none” image_loading=”default” max_width=”100%” max_width_mobile=”default”][image_with_animation image_url=”5198″ animation=”None” hover_animation=”none” alignment=”” border_radius=”none” box_shadow=”none” image_loading=”default” max_width=”100%” max_width_mobile=”default”][image_with_animation image_url=”5194″…

Advertisement This announcement is not being made in and copies of it shall not be distributed or sent, directly or…